ESC Congress 2026
- Start Date:
28 Aug 2026
- End Date:
31 Aug 2026
- Location:
Munich, Germany
- Booth #:
Booth R200 – Hall A2
Thermo Fisher Scientific is proud to be an exhibitor at ESC Congress 2026
As the PPD clinical research business of Thermo Fisher Scientific, we have global experience that spans early-phase through post-approval studies with a wealth of expertise in a wide spectrum of cardiovascular diseases, including Heart Failure, Cardiomyopathy, Lipid disorders, Coronary Artery Disease and Hypertension. Request a meeting or stop by our booth R200 – Hall A2 to learn more about our commitment to developing meaningful solutions to cardiovascular health challenges.
Enhance value with outcomes research
In today’s value-based healthcare environment, demonstrating drug efficacy alone is no longer enough. Sponsors must also prove comparative value across clinical, economic, and patient-centered outcomes. Backed by extensive experience conducting global cardiovascular outcomes studies involving thousands of sites and patients—including those with comorbidities such as type 2 diabetes, acute coronary syndrome, hypertension, dyslipidemia, and obesity—we provide the strategic, operational, and therapeutic expertise needed to deliver successful cardiovascular outcomes research.
Our capabilities include:
- Expertise in major adverse cardiac events (MACE) and event adjudication
- Advanced analytics, statistical modeling, and event rate forecasting to optimize study design and timelines
- Regulatory expertise and experience with global cardiovascular and diabetes trials
- Flexible academic research organization partnerships and proactive risk management
Through our cross-functional cardiovascular outcomes trials working group, we help sponsors improve site selection, predict event rates, and develop recovery plans that keep event-driven studies on track. Combined with a strong focus on patient engagement and retention, our approach has consistently delivered retention rates exceeding 99%.
